# Cogentus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cogentus-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Menlo Park, US
- Website: www.cogentus.net
- Total disclosed funding: $65M
- Latest round: Series D (Nov 6, 2008)
- Investors on record: 5

## About

Cogentus Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies for serious diseases, employing advanced research to create effective treatment options for patients.Founded in 2006 in Menlo Park, US, Cogentus Pharmaceuticals Inc. specializes in biopharmaceutical advancements. In November 2008, the company successfully raised USD 7.5 mn in Series D funding from investors including Prospect Venture Partners, Ridgeback Partners, and The Keffi Group. The company has engaged in a total of 4 deals to date with a current valuation of USD 161.50 mn.Cogentus Pharmaceuticals Inc. is dedicated to delivering innovative biopharmaceutical solutions aimed at enhancing patient care by advancing treatment options for serious diseases. Their focus remains on research-driven products that address unmet medical needs, particularly in the fields of oncology and autoimmune disorders, utilizing cutting-edge methodologies to create impactful therapies.Cogentus Pharmaceuticals Inc. generates revenue through strategic partnerships and collaborations with healthcare organizations, focused on the development and commercialization of its biopharmaceutical products. Their revenue model is primarily based on milestone payments and royalties linked to product sales and development achievements, ensuring a steady income stream as they progress in their clinical trials and product launches.Cogentus Pharmaceuticals Inc. aims to expand its product pipeline with several innovative therapies currently in development, targeting a launch for its lead products by the end of 2023. The company is also looking to enter new markets, particularly in Europe and Asia, by 2025, leveraging its recent Series D funding of USD 7.5 mn to support these initiatives. This funding will facilitate further research and development efforts, as well as the establishment of strategic partnerships in these new regions to enhance their market presence.

## Funding rounds

- Series D, Nov 6, 2008, $7.5M — Prospect Venture Partners, Ridgeback Partners, The Keffi Group
- Series C, Dec 31, 2007, $40M — Prospect Venture Partners, Pinnacle Ventures, Ridgeback Partners, Apothecary Capital, The Keffi Group
- Series B, Mar 6, 2007, $15M — Prospect Venture Partners
- Series A, May 31, 2006, $2M — Prospect Venture Partners

## Investors

- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series A, Series B, Series C, Series D
- Pinnacle Ventures (https://capitalatlas.ai/funds/pinnacle-ventures) — Series C
- Ridgeback Partners — Series C, Series D
- Apothecary Capital — Series C
- The Keffi Group — Series C, Series D